IL194865A - Amorophorins that are conserved in Heluaryl and their use - Google Patents

Amorophorins that are conserved in Heluaryl and their use

Info

Publication number
IL194865A
IL194865A IL194865A IL19486508A IL194865A IL 194865 A IL194865 A IL 194865A IL 194865 A IL194865 A IL 194865A IL 19486508 A IL19486508 A IL 19486508A IL 194865 A IL194865 A IL 194865A
Authority
IL
Israel
Prior art keywords
haloaryl substituted
aminopurines
substituted aminopurines
haloaryl
substituted
Prior art date
Application number
IL194865A
Other languages
English (en)
Hebrew (he)
Other versions
IL194865A0 (en
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of IL194865A0 publication Critical patent/IL194865A0/en
Publication of IL194865A publication Critical patent/IL194865A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL194865A 2006-04-26 2008-10-23 Amorophorins that are conserved in Heluaryl and their use IL194865A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/411,413 US7521446B2 (en) 2005-01-13 2006-04-26 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
PCT/US2007/010258 WO2007127382A1 (en) 2006-04-26 2007-04-25 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
IL194865A0 IL194865A0 (en) 2009-08-03
IL194865A true IL194865A (en) 2015-08-31

Family

ID=38462340

Family Applications (1)

Application Number Title Priority Date Filing Date
IL194865A IL194865A (en) 2006-04-26 2008-10-23 Amorophorins that are conserved in Heluaryl and their use

Country Status (14)

Country Link
US (2) US7521446B2 (https=)
EP (1) EP2010186B1 (https=)
JP (1) JP2009535346A (https=)
KR (1) KR20090013804A (https=)
CN (2) CN101478972A (https=)
AU (1) AU2007243287B2 (https=)
BR (1) BRPI0710805A2 (https=)
CA (1) CA2684999C (https=)
ES (1) ES2400257T3 (https=)
IL (1) IL194865A (https=)
MX (1) MX2008013616A (https=)
NZ (1) NZ572467A (https=)
WO (1) WO2007127382A1 (https=)
ZA (3) ZA200809356B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) * 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US9150507B2 (en) * 2006-04-28 2015-10-06 Shionogi & Co., Ltd. Amine derivative having NPY Y5 receptor antagonistic activity
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
US20100311807A1 (en) * 2007-03-14 2010-12-09 Washington University Methods for identifying diabetes and obesity therapeutics
SA08290668B1 (ar) * 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
US20090156598A1 (en) * 2007-12-17 2009-06-18 Lebsack Alec D Imidazolopyrimidine modulators of TRPV1
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8227618B2 (en) * 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
US20130034495A1 (en) * 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
WO2014175234A1 (ja) * 2013-04-26 2014-10-30 富士フイルム株式会社 撮像装置及び画像表示方法
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
AU2017241837B2 (en) * 2016-04-01 2021-07-22 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
RS62496B1 (sr) 2016-04-01 2021-11-30 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu
CN109563095B (zh) 2016-06-02 2021-10-29 细胞基因公司 动物和人抗疟剂
EP3464312A4 (en) * 2016-06-02 2019-11-27 Celgene Corporation ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
CN106265673B (zh) * 2016-09-18 2019-09-20 中国农业大学 一种化合物的应用
CN111417634A (zh) 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
MX2020003620A (es) 2017-10-04 2020-10-28 Celgene Corp Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
CN109384788B (zh) * 2018-10-16 2021-05-14 成都大学 嘌呤系列衍生物及其制备方法和用途
CN111544657B (zh) * 2020-05-11 2022-01-11 北京大学第三医院（北京大学第三临床医学院） 一种具有良好可打印性的细胞3d打印生物墨水制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
CA2297967A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
TR200601784T2 (tr) 1999-11-12 2007-01-22 Pharmasset Ltd. 2'-deoksi-L-nükleositlerin sentezi
ATE322494T1 (de) 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
MXPA03009361A (es) 2001-04-13 2004-01-29 Boehringer Ingelheim Pharma Compuestos de urea utilies como agentes anti-inflamatorios.
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
NZ598071A (en) 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds

Also Published As

Publication number Publication date
CN103351389B (zh) 2015-10-28
WO2007127382A1 (en) 2007-11-08
NZ572467A (en) 2010-10-29
AU2007243287B2 (en) 2012-02-16
IL194865A0 (en) 2009-08-03
AU2007243287A1 (en) 2007-11-08
US20090275564A1 (en) 2009-11-05
US8101588B2 (en) 2012-01-24
CN103351389A (zh) 2013-10-16
CA2684999C (en) 2013-11-26
ZA201103036B (en) 2012-08-29
ZA200907418B (en) 2011-12-28
JP2009535346A (ja) 2009-10-01
ZA200809356B (en) 2010-02-24
MX2008013616A (es) 2009-03-06
US7521446B2 (en) 2009-04-21
CA2684999A1 (en) 2007-11-08
BRPI0710805A2 (pt) 2011-08-16
US20070060598A1 (en) 2007-03-15
ES2400257T3 (es) 2013-04-08
EP2010186B1 (en) 2012-12-26
CN101478972A (zh) 2009-07-08
KR20090013804A (ko) 2009-02-05
EP2010186A1 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
IL194865A (en) Amorophorins that are conserved in Heluaryl and their use
TWI561237B (en) Substituted dihydropyrazolones and their use
ZA200810323B (en) Fkbp-l and uses thereof
LT2064327T (lt) Dbait ir jų panaudojimas
ZA200902189B (en) Phenylpropionamide compounds and the use thereof
SI2001556T1 (sl) Tioninijeve spojine in njihova uporaba
IL194899A0 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
ZA200903906B (en) Carboranylporphyrins and uses thereof
IL247957A0 (en) Anti-ephrinb2 antibodies and methods of using them
IL189252A0 (en) Dihydroxyanthraquinones and their use
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVE AND USE THEREOF
GB0611115D0 (en) Compounds and their use
GB0605107D0 (en) Use
IL192820A0 (en) Novel compounds and use thereof
GB0624105D0 (en) Use
GB0619611D0 (en) Compounds and their use
GB0610059D0 (en) Uses and methods
HU0600122D0 (en) New compounds and their use
GB0603378D0 (en) Compounds and their use
GB0603376D0 (en) Compounds and their use
GB0619610D0 (en) Compounds and their use
GB0616577D0 (en) Compounds and their use
GB0603374D0 (en) Compounds and their use
GB0619609D0 (en) Compounds and their use
GB0608846D0 (en) Compounds and their use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed